NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Rhea-AI Summary
NGM Biopharmaceuticals, Inc. (NGM) will host a conference call on October 17, 2022, at 8:00 a.m. ET to discuss topline efficacy and safety results from the CATALINA Phase 2 trial of NGM621, targeting geographic atrophy due to age-related macular degeneration. The trial's results are crucial for understanding the potential therapeutic impact of NGM621 on this condition. Investors can access the live webcast and slides on the company's website, which will be archived for 30 days. NGM continues to develop seven clinical programs across various therapeutic areas.
Positive
- Successful completion of the NGM621 CATALINA trial, indicating progress in clinical development.
- NGM has seven programs in clinical development, showcasing a diverse and potentially lucrative pipeline.
Negative
- None.
News Market Reaction – NGM
In the trading session that priced this news, NGM declined 70.48%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET (5:00 a.m. PT) to discuss topline efficacy and safety results from its CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration.
To access the live webcast and slides, please visit the “Investors & Media” section of NGM Bio’s website at https://ir.ngmbio.com/. The webcast will be archived for 30 days.
About NGM Bio
NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. Today, the company has seven programs in clinical development, including four in Phase 2 or 2b studies, including the recently completed NGM621 CATALINA trial, across three therapeutic areas: cancer, retinal diseases and liver and metabolic diseases. Visit us at www.ngmbio.com for more information.
| Investor Contact: Brian Schoelkopf ir@ngmbio.com | Media Contact: Liz Melone media@ngmbio.com |
